GSK executive in China bribery case
Police today accused a British executive of drug maker GlaxoSmithKline's China unit of ordering his salespeople to bribe doctors and hospitals.
It is the first time a foreign employee in China of British-based GSK has been accused in a sweeping investigation into possible misconduct by drug suppliers. Previously, police had said four Chinese managers were detained.
The British executive, Mark Reilly, is accused of operating a "massive bribery network" and pressing his sales team to pay doctors, hospital officials and health institutions to use its products, the police ministry said in a statement.
It said that resulted in "illegal revenue" of at least 1 billion yuan (£90 million).
Reilly and two Chinese executives were also accused of bribing government officials in Beijing and Shanghai, the ministry said.
Reilly was barred last year from leaving China, according to British news reports.
The case has been handed over to prosecutors, the police ministry said. It said possible charges include bribing non-government workers and bribing corporate units, while GSK might face charges of corporate bribery.